Litigation Law, Mediation Law and Arbitration Law

On June 8, 2012, Genentech’s lawsuit seeking a declaration that US Patent No. 6,733,752 was invalid and not-infringed by Genentech’s trastuzumab product (HERCEPTIN).

Last week, the D.C. Circuit held in "United States of America, ex rel. Davis v. District of Columbia", that in suits under the False Claims Act ("FCA") alleging false claims for Medicaid reimbursement, the calculation of damages must take into account the value of the medical services actually received.

On April 19, 2012, the Québec Court of Appeal (the Court) rendered the first decision on misleading advertising since the ruling of the Supreme Court of Canada (the SCC) in Richard v. Time Inc. In Perreault v. McNeil PDI Inc.,

On 16 September 2011, the Polish Parliament adopted a significant amendment to the Polish Civil Procedure Code (the "Code").

On May 9, 2012, the Securities and Exchange Commission ("SEC") charged former Detroit mayor Kwame M. Kilpatrick, former city treasurer Jeffrey W. Beasley, MayfieldGentry Realty Advisors, LLC ("MGRA") a registered investment adviser, and Mayfield the CEO and majority owner of MGRA, in connection with allegations that they were involved in a secret exchange of lavish gifts to peddle influence over Detroit’s public pension funds’ investment process.

A recent California federal court decision denied certification to a putative class of Facebook "cost-per-click" advertisers who allegedly were charged by Facebook for fraudulent or invalid clicks on their advertisements.

New private rights of action under the Competition Act (the "Act") came into force on June 20, 2025.

On June 5, 2025, in an 8-1 decision, the Supreme Court dismissed Laboratory Corporation of America Holdings v. Davis as improvidently granted—despite having already granted certiorari and heard oral argument...

In a decision issued on June 27, 2025, Trump v. CASA, Inc. (a 6-3 ruling), the U.S. Supreme Court held that federal District Courts lack authority to grant universal injunctions.

Pennsylvania’s Supreme Court has dealt a unanimous1 blow to plaintiffs’ asbestos lawyers, and potentially to plaintiffs’ lawyers in a wide range of pharmaceutical, chemical and tobacco products cases requiring scientific evidence to prove specific causation.

The Pennsylvania Supreme Court recently issued an opinion that bolsters medical device manufacturers' arsenal of defenses in design-defect products liability actions.

In an effort to avoid the impact of the completed operations aggregate limit, policyholder counsel sometimes attempt to characterize claims as (1) rip-out exposures, or (2) as relating to "abandoned or unused materials," so as to come within a common insurance policy carve-out from the Completed Operations Hazard.